Silver Diamine Fluoride Halts Childhood Cavities Without Drilling
A Phase III clinical trial led by the University of Michigan confirms that painting teeth with a simple liquid arrests decay in young children.
By Giovanni Sapere
2 min readHuman-Edited, AI-Assisted
A major multi-site clinical trial led by researchers at the University of Michigan has confirmed that painting teeth with silver diamine fluoride can arrest tooth decay in young children without drilling, injections, or sedation. The clinical discovery, published in JAMA Pediatrics, offers a low-cost medical innovation that could prevent severe dental pain and hospital surgeries for thousands of pediatric patients.
Clinical Trial Confirms Painless Arrest of Tooth Decay
Tooth decay remains the single most common chronic disease among children, affecting more than 40% of young people in the United States. In many severe cases, untreated cavities lead to infections, emergency department visits, and corrective operations performed under general anesthesia. To find a less invasive clinical innovation, a team led by Margherita Fontana, professor of dentistry at the University of Michigan School of Dentistry, conducted a Phase III clinical trial evaluating an established liquid compound as documented by ScienceDaily.
The trial enrolled 830 children under six years old across Michigan, New York, and Iowa through dental practices, pediatric clinics, and federally backed Head Start and Early Head Start programs. The findings demonstrate that a solution containing 38% silver diamine fluoride (SDF) successfully halted decay in more than half of the treated baby teeth when applied at regular six-month intervals. Rather than restoring missing enamel, the non-invasive procedure arrests active lesions by combining silver's antibacterial action with fluoride's mineral-strengthening properties.
“This is a very effective and safe treatment -- even in children as young as 1”
— Margherita Fontana, Professor of Dentistry, University of Michigan School of Dentistry
Regulatory Trajectory and Mechanism of Action
Although silver diamine fluoride is not a newly created chemical invention under an active patent, its formal adoption in mainstream American healthcare has faced regulatory hurdles. In 2014, the U.S. Food and Drug Administration cleared SDF as a medical device specifically for treating dentin hypersensitivity, prompting practitioners to use it off-label to manage active caries, as reported by ScienceDaily.
Deploying the substance takes only seconds: a clinician dips a small sponge-tipped applicator into the liquid and paints it directly onto the cavitated area. Unlike traditional restorations, the method requires no drills, local anesthetic injections, or dental operating rooms. The study notes one permanent cosmetic tradeoff: the liquid oxidizes the decayed portion of the tooth, staining damaged areas dark while leaving healthy enamel unaffected.
Expanding Access and Public Health Implications
The clinical trial commenced in 2018 and proceeded despite interruptions caused by the COVID-19 pandemic. According to the research team, providing robust data gathered directly from diverse domestic populations is a critical milestone required for full FDA approval for caries arrest.
Formal clearance for caries management could pave the way for application outside conventional dental chairs, allowing pediatricians and community clinics to offer preventive care. The researchers emphasize that beyond toddlers, the approach provides substantial therapeutic value for older adults, patients with severe dental anxiety, and individuals with physical or developmental disabilities who struggle to access standard clinical operatories, as detailed by ScienceDaily.
Read also on The Patent: Nanorobots: What it is and how it works
